In January 2003 neutron and gamma dose rate measurements at a CASTOR HAW 20/28 CG were performed by the Bundesamt für Strahlenschutz at Gorleben. First, commercial dose rate measurement devices were used, then spectral measurements with a Bonner sphere system were made to verify the results. Axial and circumferential dose rate profiles were measured near the cask surface and spectral measurements were performed for some locations. A shielding analysis of the cask was performed with the MCNP Monte Carlo Code with ENDF/B-VI cross section libraries. The cask was modelled 'as built', i.e. with its real inventory, dimensions and material densities and with the same configuration and position as in the storage facility. The average C/E-ratios are 1.3 for neutron dose rates and 1.4 for gamma dose rates. Both the measured and calculated dose rates show the same qualitative trends in the axial and circumferential direction. The spectral measurements show a variation in the spectra across the cask surface. This correlates with the variation found in the C/E-ratios. At cask midheight good agreement between the Bonner sphere system and the commercial device (LB 6411) is found with a 7% lower derived H*(10) dose rate from the Bonner sphere system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rpd/nci213 | DOI Listing |
Mil Med
January 2025
Department of Rheumatology, VA Medical Center Memphis, TN 38104, USA.
Introduction: Patients with chronic inflammatory diseases are often treated with pharmacologic therapies that target the immune system and have an increased risk of infection. These risks can be reduced by vaccination against common pathogens. This quality improvement project aimed to increase pneumococcal and herpes zoster vaccination rates in patients with chronic inflammatory disease on biologic immunosuppressive therapy.
View Article and Find Full Text PDFClin Transl Gastroenterol
January 2025
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing 100050, China.
Introduction: X842 is a new type of gastric acid-suppressing agent with a rapid onset of action and a long duration of effect. We aim to investigate the efficacy and safety of different doses of X842 versus lansoprazole in the treatment of patients with erosive esophagitis (EE).
Methods: This phase 2 study included 90 patients with EE (Los Angeles grades A-D) who were randomized (1:1:1) to receive oral low-dose X842 (50 mg/day, n=31), high-dose X842 (100 mg/day, n=31), or lansoprazole (30 mg/day, n=30) for 4 weeks.
Radiology
January 2025
From the Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 (Y.Z., D.F.Y., C.I.H.); and Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (Y.Z.).
Lung cancer is the leading cause of cancer deaths globally. In various trials, the ability of low-dose CT screening to diagnose early lung cancers leads to high cure rates. It is widely accepted that the potential benefits of low-dose CT screening for lung cancer outweigh the harms.
View Article and Find Full Text PDFANZ J Surg
January 2025
Division of Hepatobiliary-Pancreatic Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea.
Background: Preoperative biliary drainage (PBD) is commonly performed in patients with bile duct cancer (BDC). However, data regarding the timing of pancreatoduodenectomy (PD) after PBD are insufficient. This study aimed to investigate the optimal timing for surgically and oncologically safe PD after PBD.
View Article and Find Full Text PDFCureus
December 2024
Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JPN.
Background In 2024, reimbursement for gemcitabine-docetaxel therapy (GEM-DOC; gemcitabine 900 mg/m on days 1 and 8 and docetaxel 70 mg/m on day 8 every 21 days, GEM 900-DOC 70) to treat recurrent/metastatic soft tissue sarcoma (STS) was made in Japan. Methods We retrospectively reviewed clinical records of advanced/metastatic STS patients who underwent off-label gemcitabine-containing chemotherapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between February 2007 and October 2019. Results Of 115 enrolled patients, 51 were treated with GEM-DOC (26 patients received the dose as previously stated) and the other 64 with gemcitabine monotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!